Cytarabine

Generic Name
Cytarabine
Brand Names
Cytosar, Vyxeos
Drug Type
Small Molecule
Chemical Formula
C9H13N3O5
CAS Number
147-94-4
Unique Ingredient Identifier
04079A1RDZ
Background

A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication

For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Associated Therapies
-
Clinical Trials
Related News

Epacadostat, Cladribine and Cytarabine (ECC) in AML

First Posted Date
2018-04-09
Last Posted Date
2018-09-11
Lead Sponsor
Insel Gruppe AG, University Hospital Bern
Registration Number
NCT03491579
Locations
🇨🇭

Departement of Medical Oncology, University Hospital Berne, Berne, Switzerland

Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

First Posted Date
2018-04-04
Last Posted Date
2024-07-16
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
4
Registration Number
NCT03488225
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL

First Posted Date
2018-03-15
Last Posted Date
2023-02-24
Lead Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Target Recruit Count
18
Registration Number
NCT03467256
Locations
🇷🇺

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS

First Posted Date
2018-03-09
Last Posted Date
2021-12-28
Lead Sponsor
Justin Watts, MD
Target Recruit Count
12
Registration Number
NCT03459859
Locations
🇺🇸

University of Miami, Miami, Florida, United States

Epacadostat, Idarubicin and Cytarabine (EIC) in AML

First Posted Date
2018-02-23
Last Posted Date
2018-09-11
Lead Sponsor
Insel Gruppe AG, University Hospital Bern
Registration Number
NCT03444649
Locations
🇨🇭

Departement of Medical Oncology, University Hospital Berne, Berne, Switzerland

Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

First Posted Date
2018-02-22
Last Posted Date
2024-10-07
Lead Sponsor
Medical College of Wisconsin
Target Recruit Count
26
Registration Number
NCT03441048
Locations
🇺🇸

Froedtert Hospital and the Medical College of Wisconsin, Milwuakee, Wisconsin, United States

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Phase 2
Recruiting
Conditions
Clonal Cytopenia of Undetermined Significance
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Hodgkin Lymphoma
Recurrent Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Lymphoma
Chronic Myelomonocytic Leukemia
Interventions
Dietary Supplement: Ascorbic Acid
Drug: Carboplatin
Drug: Decitabine
Drug: Cisplatin
Drug: Cytarabine
Drug: Dexamethasone
Drug: Etoposide
Drug: Gemcitabine Hydrochloride
Procedure: Central Venous Cannula Insertion
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis
Other: Placebo Administration
Procedure: Portacath Placement
Other: Questionnaire Administration
Biological: Rituximab
Drug: Oxaliplatin
Procedure: Biospecimen Collection
Procedure: Core Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Echocardiography
Procedure: Positron Emission Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Computed Tomography
First Posted Date
2018-02-01
Last Posted Date
2024-08-05
Lead Sponsor
Mayo Clinic
Target Recruit Count
80
Registration Number
NCT03418038
Locations
🇺🇸

Mayo Clinic Health System-Eau Claire Clinic, Eau Claire, Wisconsin, United States

🇺🇸

Mayo Clinic Health Systems-Mankato, Mankato, Minnesota, United States

🇺🇸

Mayo Clinic Health System-Franciscan Healthcare, La Crosse, Wisconsin, United States

and more 1 locations

A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia

First Posted Date
2018-01-31
Last Posted Date
2023-04-21
Lead Sponsor
Pfizer
Target Recruit Count
730
Registration Number
NCT03416179
Locations
🇺🇸

Baylor University Medical Center, Dallas, Texas, United States

🇨🇦

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

🇵🇱

WWCOiT im. M. Kopernika w Lodzi, Lodz, Poland

and more 146 locations

A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML

Phase 2
Recruiting
Conditions
Leukemia, Myeloid
Interventions
Drug: Decitabine and Ara-C
Drug: Ara-C
First Posted Date
2018-01-31
Last Posted Date
2020-04-27
Lead Sponsor
Xuejie Jiang
Target Recruit Count
100
Registration Number
NCT03417427
Locations
🇨🇳

Nanfang Hospital of Southern Medical University, Guanzhou, Guangdong, China

RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT

Phase 2
Conditions
Myelodysplastic Syndromes
Interventions
Drug: Cytarabine
First Posted Date
2018-01-26
Last Posted Date
2022-04-20
Lead Sponsor
Peking University People's Hospital
Target Recruit Count
50
Registration Number
NCT03412266
Locations
🇨🇳

Peking University Institute of Hematology,Beijing, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy